Jennifer Jarrett Arcus Biosciences, Inc. (RCUS) insider trading activity

Jennifer Jarrett is Chief Operating Officer of Arcus Biosciences, Inc.. Currently has a direct ownership of 193,024 shares of RCUS, which is worth approximately $3.87 Million. The most recent transaction as insider was on Dec 17, 2025, when has been sold 9,983 shares (Common Stock) at a price of $22.16 per share, resulting in proceeds of $221,223. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 193K

9.9% 3M change

18.15% 12M change

Total Value Held $3.87 Million

Jennifer Jarrett Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 17 2025	SELL Open market or private sale	$221,223 $22.16 p/Share	9,983 Reduced 4.92%	193,024 Common Stock
Dec 16 2025	SELL Open market or private sale	$245,603 $21.88 p/Share	11,225 Reduced 5.24%	203,007 Common Stock
Nov 07 2025	SELL Open market or private sale	$954,020 $18.97 p/Share	50,291 Reduced 19.01%	214,232 Common Stock
Nov 07 2025	BUY Exercise of conversion of derivative security	$61,857 $1.23 p/Share	50,291 Added 15.97%	264,523 Common Stock
Oct 08 2025	SELL Open market or private sale	$568,769 $15.05 p/Share	37,792 Reduced 15.0%	214,232 Common Stock
Oct 08 2025	BUY Exercise of conversion of derivative security	$46,484 $1.23 p/Share	37,792 Added 13.04%	252,024 Common Stock
Oct 06 2025	SELL Open market or private sale	$181,750 $14.54 p/Share	12,500 Reduced 5.51%	214,232 Common Stock

Oct 06 2025	BUY Exercise of conversion of derivative security	$15,375 $1.23 p/Share	12,500 Added 5.23%	226,732 Common Stock
Jan 23 2025	BUY Grant, award, or other acquisition	-	50,000 Added 18.98%	213,369 Common Stock
Dec 15 2024	SELL Payment of exercise price or tax liability	$442,216 $16.08 p/Share	27,501 Reduced 14.41%	163,369 Common Stock
Sep 15 2024	SELL Payment of exercise price or tax liability	$227,426 $17.95 p/Share	12,670 Reduced 6.24%	190,394 Common Stock
Jun 15 2024	SELL Payment of exercise price or tax liability	$215,009 $16.97 p/Share	12,670 Reduced 5.87%	203,064 Common Stock
Mar 27 2024	SELL Open market or private sale	$202,720 $17.55 p/Share	11,551 Reduced 5.09%	215,253 Common Stock
Mar 18 2024	SELL Open market or private sale	$245,175 $18.23 p/Share	13,449 Reduced 5.6%	226,804 Common Stock
Feb 27 2024	SELL Open market or private sale	$685,147 $20.11 p/Share	34,070 Reduced 12.42%	240,253 Common Stock
Feb 26 2024	SELL Open market or private sale	$492,818 $20.07 p/Share	24,555 Reduced 8.22%	274,323 Common Stock
Jan 23 2024	BUY Grant, award, or other acquisition	-	40,000 Added 11.8%	298,878 Common Stock
Dec 22 2023	SELL Open market or private sale	$382,212 $17.76 p/Share	21,521 Reduced 7.68%	258,878 Common Stock
Dec 19 2023	SELL Sale (or disposition) back to the issuer	$207,890 $18.09 p/Share	11,492 Reduced 3.94%	280,399 Common Stock
Dec 18 2023	SELL Sale (or disposition) back to the issuer	$199,574 $17.74 p/Share	11,250 Reduced 3.71%	291,891 Common Stock
Sep 22 2023	SELL Open market or private sale	$427,166 $19.99 p/Share	21,369 Reduced 6.59%	302,691 Common Stock
Sep 18 2023	SELL Sale (or disposition) back to the issuer	$255,122 $20.4 p/Share	12,506 Reduced 3.72%	324,060 Common Stock
Jul 28 2023	SELL Open market or private sale	$911,250 $20.25 p/Share	45,000 Reduced 11.79%	336,566 Common Stock
Jun 22 2023	SELL Open market or private sale	$237,795 $19.12 p/Share	12,437 Reduced 3.16%	381,566 Common Stock
Jun 16 2023	SELL Open market or private sale	$243,094 $19.35 p/Share	12,563 Reduced 3.09%	394,003 Common Stock

Also insider at

SNDX

Syndax Pharmaceuticals Inc Healthcare

ARNA

ARENA PHARMACEUTICALS INC Healthcare

Director

SRZN

Surrozen, Inc. Healthcare

RDUS

Radius Health, Inc. Healthcare

Director

JATT-WT

JATT Acquisition Corp

SGMT

Sagimet Biosciences Inc.

Director